New targeted drug trial offers hope for Tough-to-Treat liver cancer
NCT ID NCT07239986
Summary
This study is testing an experimental drug called BB102 for people with advanced liver cancer that has worsened despite standard treatments. The goal is to see if the drug can shrink tumors and control the cancer's growth. About 60 participants with a specific type of liver cancer will receive the drug to measure its effectiveness and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, 230031, China
Contact Phone: •••-•••-••••
-
Zhongshan Hospital
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.